{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:45:41Z","timestamp":1763531141434,"version":"3.45.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"DOI":"10.7759\/cureus.97192","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:42:58Z","timestamp":1763530978000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of a Fixed-Dose Combination of Dapagliflozin and Vildagliptin in the Treatment of Type 2 Diabetes Mellitus: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Ami","family":"Sanghvi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sona","family":"Warrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo RA","year":"2009","unstructured":"Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009, 58:773-95. 10.2337\/db09-9028","journal-title":"Diabetes"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.47191\/ijcsrr\/V6-i3-19","article-title":"The use of vildagliptin-dapagliflozin fixed-dose combination in different patient profiles in Indian settings: an opinion-based consensus","volume":"6","author":"Agrawala R","year":"2023","unstructured":"Agrawala R, Akbar S, Biswas K, et al.. The use of vildagliptin-dapagliflozin fixed-dose combination in different patient profiles in Indian settings: an opinion-based consensus. Int J Curr Sci Res Rev. 2023, 6:2010-7. 10.47191\/ijcsrr\/V6-i3-19","journal-title":"Int J Curr Sci Res Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16550","article-title":"Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: an updated systematic review and meta-analysis with focus on an Asian subpopulation","volume":"27","author":"Kim MJ","year":"2025","unstructured":"Kim MJ, Cho YK, Kim S, Moon JY, Jung CH, Lee WJ. Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: an updated systematic review and meta-analysis with focus on an Asian subpopulation. Diabetes Obes Metab. 2025, 27:5019-31. 10.1111\/dom.16550","journal-title":"Diabetes Obes Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies MJ","year":"2018","unstructured":"Davies MJ, D'Alessio DA, Fradkin J, et al.. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018, 41:2669-701. 10.2337\/dci18-0033","journal-title":"Diabetes Care"},{"key":"ref5","article-title":"Sodium-glucose transport protein 2 (SGLT2) inhibitors","author":"Padda IS","year":"2025","unstructured":"Padda IS, Mahtani AU, Parmar M. Sodium-glucose transport protein 2 (SGLT2) inhibitors. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/11795514231203911","article-title":"Expert evaluation of efficacy and rationality of vildagliptin \"EVER-Vilda\": an Indian perspective","volume":"17","author":"Kalra S","year":"2024","unstructured":"Kalra S, Zargar AH, Sridhar GR, et al.. Expert evaluation of efficacy and rationality of vildagliptin \"EVER-Vilda\": an Indian perspective. Clin Med Insights Endocrinol Diabetes. 2024, 17:11795514231203911. 10.1177\/11795514231203911","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.58115","article-title":"Evaluating the efficacy, safety, and tolerability of combination therapy of dapagliflozin and linagliptin over dapagliflozin and vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with metformin","volume":"16","author":"Dharmalingam M","year":"2024","unstructured":"Dharmalingam M, Kumar Sharma S, Prakash V, et al.. Evaluating the efficacy, safety, and tolerability of combination therapy of dapagliflozin and linagliptin over dapagliflozin and vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with metformin. Cureus. 2024, 16:58115. 10.7759\/cureus.58115","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/ijdt.ijdt_24_24","article-title":"Vildagliptin sustained-release and dapagliflozin fixed-dose combination in the management of type 2 diabetes mellitus: a comprehensive review","volume":"3","author":"Ghosh S","year":"2024","unstructured":"Ghosh S, Mukhopadhyay M, Agrawal M, et al.. Vildagliptin sustained-release and dapagliflozin fixed-dose combination in the management of type 2 diabetes mellitus: a comprehensive review. Int J Diabetes Mellit. 2024, 3:49-54. 10.4103\/ijdt.ijdt_24_24","journal-title":"Int J Diabetes Mellit"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2011.01323.x","article-title":"The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"37","author":"Cai L","year":"2012","unstructured":"Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2012, 37:386-98. 10.1111\/j.1365-2710.2011.01323.x","journal-title":"J Clin Pharm Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01659.x","article-title":"Dapagliflozin monotherapy in drug-na\u00efve patients with diabetes: a randomized-controlled trial of low-dose range","volume":"14","author":"Bailey CJ","year":"2012","unstructured":"Bailey CJ, Iqbal N, T'joen C, List JF. Dapagliflozin monotherapy in drug-na\u00efve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012, 14:951-9. 10.1111\/j.1463-1326.2012.01659.x","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12624","article-title":"Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial","volume":"32","author":"Bailey CJ","year":"2015","unstructured":"Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF. Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med. 2015, 32:531-41. 10.1111\/dme.12624","journal-title":"Diabet Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016575","article-title":"Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"98","author":"Feng M","year":"2019","unstructured":"Feng M, Lv H, Xu X, Wang J, Lyu W, Fu S. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019, 98:16575. 10.1097\/MD.0000000000016575","journal-title":"Medicine (Baltimore)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/jod.jod_93_23","article-title":"Diabetes and current Indian scenario: a narrative review","volume":"15","author":"Muralidharan S","year":"2024","unstructured":"Muralidharan S. Diabetes and current Indian scenario: a narrative review. J Diabetol. 2024, 15:12. 10.4103\/jod.jod_93_23","journal-title":"J Diabetol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39204","article-title":"Sustained-release vildagliptin 100 mg in type 2 diabetes mellitus: a review","volume":"15","author":"Sridhar GR","year":"2023","unstructured":"Sridhar GR, Pandit K, Warrier S, Birla A. Sustained-release vildagliptin 100 mg in type 2 diabetes mellitus: a review. Cureus. 2023, 15:39204. 10.7759\/cureus.39204","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.01.011","article-title":"Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: a systematic review and meta-analysis","volume":"44","author":"Cho YK","year":"2018","unstructured":"Cho YK, Kang YM, Lee SE, et al.. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2018, 44:393-401. 10.1016\/j.diabet.2018.01.011","journal-title":"Diabetes Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111814","article-title":"\u03b2-cell function and long-term glycemic control in patients newly diagnosed with type 2 diabetes with moderate hyperglycemia after a 6-month course of basal insulin therapy","volume":"215","author":"Kuo CS","year":"2024","unstructured":"Kuo CS, Chen HS. \u03b2-cell function and long-term glycemic control in patients newly diagnosed with type 2 diabetes with moderate hyperglycemia after a 6-month course of basal insulin therapy. Diabetes Res Clin Pract. 2024, 215:111814. 10.1016\/j.diabres.2024.111814","journal-title":"Diabetes Res Clin Pract"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey CJ","year":"2010","unstructured":"Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010, 375:2223-33. 10.1016\/S0140-6736(10)60407-2","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.37349\/eemd.2025.101428","article-title":"Updates from the 2025 American Diabetes Association guidelines on standards of medical care in diabetes","volume":"2","author":"Tiwari D","year":"2025","unstructured":"Tiwari D, Loh WJ, Aw TC. Updates from the 2025 American Diabetes Association guidelines on standards of medical care in diabetes. Explor Endocr Metab Dis. 2025, 2:101428. 10.37349\/eemd.2025.101428","journal-title":"Explor Endocr Metab Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/423105-effectiveness-and-safety-of-a-fixed-dose-combination-of-dapagliflozin-and-vildagliptin-in-the-treatment-of-type-2-diabetes-mellitus-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:42:58Z","timestamp":1763530978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/423105-effectiveness-and-safety-of-a-fixed-dose-combination-of-dapagliflozin-and-vildagliptin-in-the-treatment-of-type-2-diabetes-mellitus-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.97192","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}